Rectal Artery Infusion Chemotherapy of Oxaliplatin Plus Capecitabine Combined With Anti-PD1 Antibody After Induction Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer a Prospective Single-arm Phase II Study
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Sintilimab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms RAIC
Most Recent Events
- 24 Oct 2023 Results (n=20) assessing the effectiveness and safety of rectal arterial infusion chemotherapy combined with anti-PD1 antibody for microsatellite stable locally advanced rectal cancer, presented at the 48th European Society for Medical Oncology Congress.
- 12 Jun 2023 Planned primary completion date changed from 25 Apr 2023 to 25 Apr 2024.
- 25 Apr 2022 Planned End Date changed from 20 Apr 2025 to 25 Apr 2025.